Do you find data from phase 2 DESTINY-LUNG01 study sufficient to change practice in HER2 mutant NSCLC or is a phase 3 study still needed?  

How does trastuzumab deruxtecan compare to other HER2 targeted strategies?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at St. Luke's Episcopal Hospital
Pulmonary fibrosis is a known toxicity of this dru...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution